Clinical Trial Update: Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update on talactoferrin added to standard chemotherapy for non-small cell lung cancer, reporting safety and efficacy findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Talactoferrin (talactoferrin)

Snippet

Sponsor: Agennix | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN